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BACKGROUND: Only a few clinical trials have been conducted in patients with advanced pancreatic cancer after failure of first-line
gemcitabine-based chemotherapy. Therefore, there is no current consensus on the treatment of these patients. We conducted a
randomised phase II study of the modified FOLFIRI.3 (mFOLFIRI.3; a regimen combining 5-fluorouracil (5-FU), folinic acid, and
irinotecan) and modified FOLFOX (mFOLFOX; a regimen combining folinic acid, 5-FU, and oxaliplatin) regimens as second-line
treatments in patients with gemcitabine-refractory pancreatic cancer.
METHODS: The primary end point was the 6-month overall survival rate. The mFOlFIRI.3 regimen consisted of irinotecan (70mgm
 2;
days 1 and 3), leucovorin (400mgm
 2; day 1), and 5-FU (2000mgm
 2; days 1 and 2) every 2 weeks. The mFOLFOX regimen was
composed of oxaliplatin (85mgm
 2; day 1), leucovorin (400mgm
 2; day 1), and 5-FU (2000mgm
 2; days 1 and 2) every 2 weeks.
RESULTS: Sixty-one patients were randomised to mFOLFIRI.3 (n¼31) or mFOLFOX (n¼30) regimen. The six-month survival
rates were 27% (95% confidence interval (CI)¼13–46%) and 30% (95% CI¼15–49%), respectively. The median overall survival
periods were 16.6 and 14.9 weeks, respectively. Disease control was achieved in 23% (95% CI¼10–42%) and 17% patients
(95% CI¼6–35%), respectively. The number of patients with at least one grade 3/4 toxicity was identical (11 patients, 38%) in both
groups: neutropenia (7 patients under mFOLFIRI.3 regimen vs 6 patients under mFOLFOX regimen), asthaenia (1 vs 4), vomiting
(3 in both), diarrhoea (2 vs 0), and mucositis (1 vs 2).
CONCLUSION: Both mFOLFIRI.3 and mFOLFOX regimens were tolerated with manageable toxicity, offering modest activities as
second-line treatments for patients with advanced pancreatic cancer, previously treated with gemcitabine.
British Journal of Cancer (2009) 101, 1658–1663. doi:10.1038/sj.bjc.6605374 www.bjcancer.com
Published online 13 October 2009
& 2009 Cancer Research UK
Keywords: second-line chemotherapy; pancreatic cancer; irinotecan; oxaliplatin; gemcitabine
                                                             
Pancreatic cancer accounts for 3% of all cancers, but is the fifth
leading cause of cancer death in Western countries (Yeo et al,
2005). At the time of diagnosis, approximately half of the patients
have metastases, and the median survival time barely exceeds
6 months, whereas approximately one-third of patients diagnosed
with locally advanced disease have median survival times ranging
between 6 and 9 months. Thus, a small proportion of patients are
eligible for surgery, the only curative treatment option, at
diagnosis (Bilimoria et al, 2007). Even with surgery, prognosis
remains poor; the 5-year overall survival was only 23.4% for
patients undergoing pancreatectomy (Sener et al, 1999).
Although 5-fluorouracil (5-FU)-based chemotherapy has been
reported to be superior to best supportive care alone (Palmer et al,
1994; Glimelius et al, 1996), and a pivotal phase III trial showed
that gemcitabine offers a survival advantage over a weekly bolus
infusion of 5-FU, accompanied by an improved clinical benefit
(Burris et al, 1997), the overall therapeutic results are still
disappointing; the response rate was 5.4% with a clinical benefit
response rate of 23.8% and a 1-year survival rate of 18% in patients
treated with gemcitabine.
Therefore, a number of clinical studies have been undertaken to
enhance the effectiveness of front-line chemotherapy. Despite
promising results in early-phase clinical studies, the majority of
newer approaches have failed to show clinically meaningful
therapeutic advantages over the standard infusion of gemcitabine
alone. Although regimens consisting of gemcitabine in combina-
tion with erlotinib or capecitabine have shown statistically signi-
ficant increases in survival duration, the small amount of survival
benefit and accompanying toxicities result in difficulties related
to their translation into clinically meaningful improvements
(Cunningham et al, 2005; Moore et al, 2007).
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sConsidering the poor response rate (20% or less) of gemcita-
bine-based doublet treatment in the first-line setting, the short
progression-free survival (PFS) (o4 months), and the increased
use of gemcitabine as adjuvant treatment (Oettle et al, 2007), an
additional problem in the therapeutic management of this
common malignant disease, is the need for effective treatment
alternatives in patients failing to respond to gemcitabine-based
chemotherapy. To date, few studies have assessed second-line
chemotherapy, primarily because of poor prognosis (Nakachi et al,
2007) and because of the limited life expectancy of those with
advanced pancreatic cancer after failure of first-line chemotherapy
(Kozuch et al, 2001; Tsavaris et al, 2005; Kulke et al, 2007; Xiong
et al, 2008; Novarino et al, 2009). There is, therefore, a growing
unmet need for a second-line chemotherapy regimen to treat
patients with gemcitabine-refractory pancreatic cancer (Boeck and
Heinemann, 2008; Kang and Saif, 2008).
The clinical benefit and safety of the FOLFIRI and FOLFOX
regimens have been well established in a study of gastrointestinal
cancer patients (Tournigand et al, 2004). In several phase II trials,
irinotecan-based and oxaliplatin-based regimens have shown
modest activity against advanced pancreatic cancer. A French
group has reported that the FOLFIRI.3 regimen, composed of a
split irinotecan infusion on days 1 and 3, with 5-FU for 2 days,
showed promising activity in chemotherapy-naive and pre-treated
patients with advanced pancreatic cancer. The confirmed response
rate was 37.5%, with a median PFS of 5.6 months (Taieb et al,
2007). The study also suggested that there was no cross-resistance
between gemcitabine and FOLFIRI.3 regimen. Furthermore, an
oxaliplatin and 5-FU combination, at various doses and schedules,
has been evaluated as second-line chemotherapy in pancreatic
cancer patients after gemcitabine failure (Tsavaris et al, 2005;
Gebbia et al, 2007; Novarino et al, 2009). Recently, a German group
has reported that the 5FU/folinic acid (FA) plus oxaliplatin (OFF)
regimen could prolong survival and improve the quality of life of
advanced pancreatic cancer patients after gemcitabine failure
compared with best supportive care alone with or without 5FU/FA
(FF) (Oettle et al, 2005; Pelzer et al, 2008).
On the basis of these results, we conducted a randomised phase
II study of the modified FOLFIRI.3 (mFOLFIRI.3) and modified
FOLFOX (mFOLFOX) regimens as second-line treatments in
patients with gemcitabine-refractory pancreatic cancer. The aim
of this study was to select a better regimen, which should be inves-
tigated in future studies.
MATERIALS AND METHODS
Patients
Patients at least 18 years of age with histologically confirmed,
locally advanced, or metastatic pancreatic adenocarcinoma, who
were previously treated with gemcitabine-based first-line chemo-
therapy were eligible for this study if they met the following
inclusion criteria: Eastern Cooperative Oncology Group (ECOG)
performance status (PS) 0–2; measurable disease based on
Response Evaluation Criteria in Solid Tumors (RECIST) criteria;
no previous second-line chemotherapy; adequate bone marrow
function, defined as a condition with leukocyte count 44000 per
ml, absolute neutrophil count 41500 per ml, haemoglobin 49.0g
per 100ml, platelets 4100000 per ml; adequate renal and hepatic
function, defined as a condition with serum creatinine o1.5mg
per 100ml, bilirubin o1.5mg per 100ml (o2.5mg per 100ml in
patients with obstructive jaundice and adequately decompressed
bile duct obstruction), and serum transaminase othree-fold the
upper normal limit (ofive-fold the upper normal limit for patients
with liver metastasis); adequate nutritional status, defined as a
condition with albumin 43.0g per 100ml; and the giving of written
informed consent. Patients were excluded if they had histology
indicating a condition other than adenocarcinoma, brain meta-
stasis, significant gastrointestinal bleeding or obstruction, any
serious co-morbidity, axial skeletal radiotherapy within 6 months
before study commencement, or peripheral neuropathy of grade 2
or worse. This study was initially approved by the Institutional
Review Board of the Asan Medical Center. The study was con-
ducted according to the tenets of the Declaration of Helsinki and
guidelines on good clinical practice. The clinical trial registration
number was NCT00786006.
Study design and randomisation
This was an open-label, single-centre, randomised phase II trial
using the two treatment arms of mFOLFIRI.3 and mFOLFOX.
Random assignment was performed at a 1:1 ratio and patients
were stratified by age (p65 years vs 465 years), ECOG PS (0–1 vs 2),
and an earlier best overall response to gemcitabine (non-disease
progression vs disease progression).
Treatment dose and schedule
The mFOlFIRI.3 regimen consisted of irinotecan 70mgm
 2 (over
1h) on day 1, leucovorin 400mgm
 2 (over 2h) on day 1, 5-FU
2000mgm
 2 (over 46h) from day 1, and irinotecan 70mgm
 2
(over 1h) at the end of the 5-FU infusion every 2 weeks. The
mFOLFOX regimen was composed of oxaliplatin 85mgm
 2 (over
2h) on day 1, leucovorin 400mgm
 2 (over 2h) on day 1, and 5-FU
2,000mgm
 2 (over 46h) every 2 weeks. When haematologic or
non-haematologic toxicities of grade X2 occurred, chemotherapy
was delayed until recovery to grade p1. The doses of subsequent
schedules were reduced by 25% in patients with grade X3
haematologic and non-haematologic toxicities, and if toxicity was
considered to be attributable, by the attending physician, to only
one drug; the doses of other drugs were not modified. Treatment
was continued until the occurrence of disease progression,
unacceptable toxicity, or patient’s refusal to continue. If disease
progression was observed and patient performance was good,
crossover to the alternate treatment arm was permitted.
Pre- and on-treatment evaluation
Within 2 weeks before study enrolment, patients gave a complete
medical history; underwent a full physical examination including
ECOG PS; were sampled for a complete blood count, serum
chemistry with electrolyte levels, a coagulation battery, and
carbohydrate antigen 19–9 (CA 19–9) level; underwent urinalysis;
underwent a chest X-ray; were assessed by electrocardiography;
and were evaluated by computed tomography of the abdomen and
pelvis (chest or any other region, if metastasis was suspected or
previously detected). Before the administration of each cycle of
chemotherapy, each patient was examined and reviewed for
complete and differential blood counts and serum chemistry.
More frequent review and monitoring were performed if clinically
indicated. Tumour response was assessed every three cycles accor-
ding to the RECIST criteria (Therasse et al, 2000). For each of these
assessments, similar imaging techniques as used at baseline were
used. The National Cancer Institute Common Terminology
Criteria for Adverse Events, version 3.0, was used to assess toxicity.
Statistical analysis
The primary end point was the 6-month survival rate. The
randomised two-arm phase II design was used to select the more
promising regimen of the two in terms of this criterion (Simon
et al, 1985). Using this design, the regimen with the better survival
rate is selected, irrespective of the difference between protocols. To
permit at least a 90% probability of selecting a truly better regimen
when the absolute difference in the 6-month survival rate was 15%
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sor greater, 29 evaluable patients were needed in each arm. Survival
time was calculated from the date of randomisation to the date of
death from any cause. The secondary end points were overall
response rate, PFS, overall survival (OS), and toxicity. Overall
response rate was analysed on an intention-to-treat basis. PFS was
defined as the time from randomisation to disease progression or
death from any cause. PFS was censored at the date of the last visit
for those patients who were alive without documented disease
progression. OS and PFS were estimated by the Kaplan–Meier
method. Patients were considered assessable if they had received at
least two cycles of chemotherapy (over 4 weeks) and had at least
one follow-up imaging study. However, patients were also
considered assessable if they received less than two cycles because
of rapid tumour progression. Survival curves were compared by
the log-rank test. In multivariate analysis, Cox’s proportional
hazards model was used to identify independent prognostic factors
for PFS and OS. All tests were two-sided and a P-value o0.05 was
considered to be statistically significant. SPSS version 14.0 (SPSS,
Chicago, IL, USA) was used for statistical analysis.
RESULTS
Patient characteristics
From January 2007 to December 2008, 61 pancreatic cancer
patients were enrolled at the Asan Medical Center, Seoul, Korea; 31
were randomly assigned to the mFOLFIRI.3 arm and 30 to the
mFOLFOX arm. One patient in the mFOLFIRI.3 arm withdrew
consent after the first cycle of chemotherapy and was lost to
follow-up. Baseline characteristics were well balanced between the
two treatment arms (Table 1). The median patient age was 55 years
(range 35–73 years) and all but one patient was of ECOG PS 0 or 1.
Twenty-one patients (34%) had undergone previous surgery and
two (3%) had received palliative radiotherapy. Of the 16 patients
who were prescribed adjuvant chemotherapy, gemcitabine was
administered to three patients. Gemcitabine plus capecitabine was
given to most patients (75%). After disease progression to a stage
at which a salvage regimen was required, a crossover to the
alternate protocol was undertaken by 12 patients (39%) in the
mFOLFIRI.3 arm and by 7 (23%) in the mFOLFOX arm. The
median time to crossover to the alternate treatment was 8.3 weeks
(range 3.3–18.1 weeks) in the mFOLFIRI.3 arm, and 15 weeks
(range 7.0–32.6 weeks) in the mFOLFOX arm.
Primary end points
A total of 98 cycles of the mFOLFIRI.3 and 93 cycles of the
mFOLFOX regimens were delivered with a median of 3 cycles
(range 1–12 and 1–10 cycles, respectively) in both arms. With a
median follow-up period of 24.4 weeks (range 0.8–40.8 weeks), 50
of 61 patients (82%) died. The 6-month survival rate was 27% in
the mFOLFIRI.3 arm (95% confidence interval (CI)¼13–46%)
patients and 30% for those in the mFOLFOX arm (95% CI¼15–
49%). Except for two patients who died because of treatment-
related complications, all deaths were attributable to disease
progression per se.
Secondary end points
The overall response rate values are listed in Table 2. Response
evaluation was possible in 28 patients in the mFOLFIRI.3 arm and
in 26 patients in the mFOLFOX arm. In the mFOLFIRI.3 arm, two
patients could not be evaluated because of early death, and were
lost to follow-up before the first response evaluation. In the
mFOLFOX arm, response evaluation could not be achieved in four
patients because of early death (two patients), loss to follow-up
(one patient), and patient’s refusal to continue with the trial
(one patient). The overall response rate in the intention-to-treat
population was 7% in the mFOLFOX arm (95% CI¼1–22%).
Overall response could not be ascertained in the mFOLFIRI.3 arm.
The disease control rate (PR and stable disease) was 23% in the
mFOLFIRI.3 arm (95% CI¼11–40%) and 17% in the mFOLFOX
arm (95% CI¼7–34%).
Table 1 Patient characteristics
Characteristic
mFOLFIRI.3
(n¼31)
No. of patients (%)
mFOLFOX
(n¼30)
No. of patients (%)
Age, median (range) 55 (37–73) 55 (35–69)
o60 years 19 (61) 18 (60)
X60 years 12 (39) 12 (40)
Gender
Male 24 (77) 20 (67)
Female 7 (23) 10 (33)
ECOG PS
0 5 (16) 5 (17)
1 26 (84) 24 (80)
2 0 (0) 1 (3)
Metastatic site
Liver 19 (61) 21 (70)
Peritoneum 19 (61) 11 (37)
Lung 6 (19) 5 (17)
Lymph nodes 15 (48) 14 (47)
Others 9 (29) 5 (17)
Prior treatment
Surgery 10 (32) 11 (37)
Palliative radiotherapy 1 (3) 1 (3)
Adjuvant chemotherapy 7 (23) 9 (30)
Neoadjuvant
chemoradiotherapy
0 (0) 1 (3)
Prior gemcitabine-based regimen
Gemcitabine 4 (13) 2 (7)
Gemcitabine/capecitabine 20 (64) 26 (86)
Gemcitabine/erlotinib 4 (13) 2 (7)
Gemcitabine/cisplatin 3 (10) 0 (0)
Previous response to gemcitabine-based regimen
CR 0 (0) 1 (3)
PR 10 (32) 9 (30)
SD 11 (35) 13 (43)
PD 10 (32) 7 (23)
Survival at analysis
Alive 6 (20) 5 (17)
Dead 25 (81) 25 (83)
Crossover to alternative
regimen
12 (39) 7 (23)
Abbreviations: ECOG PS¼Eastern Cooperative Oncology Group performance
status; CR¼complete response; PR¼partial response; SD¼stable disease;
PD¼progressive disease.
Table 2 Overall response rate
Overall Response
mFOLFIRI.3
No. of patients
(%, 95% CI)
mFOLFOX
No. of patients
(%, 95% CI)
PR 0 (0, 0–10) 2 (7, 1–22)
SD 7 (23, 11–40) 3 (10, 3–26)
PD 21 (68, 49–83) 21 (70, 52–84)
Not evaluable 3 (10, 3–26) 4 (13, 5–30)
Disease control 7 (23, 11–40) 5 (17, 7–34)
Abbreviations: PR¼partial response; SD¼stable disease; PD¼progressive disease.
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mFOLFIRI.3 (95% CI¼6.9–9.6 weeks) and 6.0 weeks for those
given mFOLFOX (95% CI¼5.1–6.9 weeks) (Figure 1). The median
OS was 16.6 weeks for patients treated with mFOLFIRI.3 (95%
CI¼12.5–20.6 weeks) and 14.9 weeks for those given mFOLFOX
(95% CI¼8.0–21.8 weeks) (Figure 1). Turning to survival
outcomes from the commencement of first-line chemotherapy,
the median PFS was 34.9 weeks (95% CI¼30.8–38.9 weeks) and
37.0 weeks (95% CI¼32.0–42.0 weeks) for mFOLFIRI.3 and
mFOLFOX, respectively. The median OS was identical at 47.1 weeks
(95% CI¼39.0–55.2 weeks and 36.0–58.3 weeks, respectively).
Toxicity
The numbers of patients experiencing adverse events are presented
in Table 3. In each treatment arm, 29 patients were available for
toxicity assessment, and only two patients in the mFOLFOX arm
were free from adverse events. The prevalence of severe toxicities
was the same between the two regimens (38%); however, grade 3/4
asthaenia (3% vs 14%) developed more frequently in patients
receiving mFOLFOX, whereas grade 3/4 diarrhoea (7% vs 0%) was
more common in patients prescribed mFOLFIRI.3. Treatment-
related mortality occurred in one patient in each group. One
patient in the mFOLFIRI.3 arm died of septic shock complicated
by febrile neutropaenia after 2 weeks of the first cycle. In one
patient in the mFOLFOX arm, early death after the first cycle of
chemotherapy was caused by severe pneumonia.
Prognostic factors
In a univariate analysis of survival outcomes according to the
clinical variables of all 60 patients (gender, age, ECOG PS,
hypoalbuminaemia, anaemia, resectability at initial diagnosis, liver
metastasis, and PFS under gemcitabine), hypoalbuminaemia
(p3.5mg100ml
 1) and ECOG PS X1 were significant prognostic
factors for poor PFS and OS. In multivariate analysis, however,
only hypoalbuminaemia predicted poor PFS (P¼0.02, hazard
ratio¼1.97, 95% CI¼1.14–3.39), but not OS.
DISCUSSION
Pancreatic cancer is well known to be refractive to chemotherapy
and to show rapid progression. Until recently, patients with
pancreatic cancer after gemcitabine-based chemotherapy failure
have had little opportunity to receive second-line chemotherapy
because of rapid performance deterioration (Nakachi et al, 2007;
Kang and Saif, 2008). Therefore, few studies have focused on
patients with advanced pancreatic cancer in a second-line setting.
Moreover, as gemcitabine is known to be effective when used as
adjuvant therapy, many patients who underwent curative resection
received gemcitabine in this setting. This means that oncologists
urgently require data on other chemotherapeutic options for
gemcitabine-pretreated patients.
Gemcitabine plus oxaliplatin (GEMOX), oxaliplatin plus cape-
citabine (XELOX), capecitabine plus erlotinib, docetaxel plus
gefitinib, and FOLFOX have been tested in gemcitabine-refractory
pancreatic cancer patients and showed disease control rates of
19–53% and a median OS range of 2.9–6.7 months (Tsavaris et al,
2005; Demols et al, 2006; Kulke et al, 2007; Xiong et al, 2008; Brell
et al, 2009; Novarino et al, 2009). Recently, another oxaliplatin-
based regimen, 5-FU/FA plus oxaliplatin (OFF), was shown to offer
significantly improved survival compared with 5-FU/FA (FF) in a
phase III trial (CONKO 003) (Pelzer et al, 2008). In this
randomised trial, including 160 gemcitabine-pretreated patients
with advanced pancreatic cancer, patients receiving OFF achieved
a median PFS of 13 weeks (P¼0.012) and a median OS of 26 weeks
(P¼0.014), compared with 9 and 13 weeks, respectively, for
FF-treated patients. However, there is no current consensus on
optimal second-line therapy for gemcitabine-refractory advanced
pancreatic cancer (Boeck and Heinemann, 2008; Kang and Saif,
2008). Both FOLFIRI.3 and FOLFOX have shown modest activity as
first-line and second-line chemotherapy regimens (Tsavaris et al,
2005; Gebbia et al, 2007; Taieb et al, 2007; Novarino et al, 2009).
We were also of the view that neither regimen showed significant
cross-resistance to gemcitabine-based protocols (Gebbia et al,
2007; Taieb et al, 2007).
The results of this trial show that both combination regimens
showed favourable efficacy and toxicity profiles in gemcitabine-
pretreated patients with advanced pancreatic cancer. The 6-month
survival rates were 27 and 30% and disease control rates were 23%
and 17%, in patients treated with mFOLFIRI.3 and mFOLFOX,
respectively. Of the 12 patients whose disease was controlled by
these regimens, disease stabilisation was previously achieved in
nine patients in gemcitabine-based regimens. The median PFS and
median OS were 8.3 weeks and 16.6 weeks in the mFOLFIRI.3 arm,
and 6.0 weeks and 14.9 weeks in the mFOLFOX arm, respectively.
These were in line with the survival data of several previous studies
(Tsavaris et al, 2005; Gebbia et al, 2007; Novarino et al, 2009).
Toxicities related to both regimens were quite expectable and
generally manageable. Patients with toxicities of grade 3 or worse
constituted 38% of each treatment arm. Common toxicities of both
regimens included anaemia, neutropenia, asthaenia, nausea, vomi-
ting, and mucositis. In accordance with the known toxicities of
both regimens, diarrhoea developed more frequently in mFOL-
FIRI.3 arm patients and neuropathy was more common in those in
the mFOLFOX arm. Although half the patients treated with
mFOLFOX experienced peripheral neuropathy, this was mostly of
grade 1. This may be related to a lower cumulative dose of oxali-
platin because of the early dropout caused by rapid disease pro-
gression. However, treatment-related mortality occurred in patients
prescribed either regimen, and hence physicians need to guard against
infectious complications in patients treated with these protocols.
Turning to prognostic factors affecting PFS and OS, hypoalbu-
minaemia, implying poor nutritional status, was a poor prognostic
factor for PFS in this study. In contrast to a previous study (Herrmann
et al, 2008), we could not find an association between the time to
progression under first-line chemotherapy (p6 months) and PFS
under second-line therapy, or residual survival. However, it is hard
to draw conclusions with regard to this, because this study had
small sample sizes, which might result in insufficient statistical
power detecting significant prognostic factors.
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Figure 1 Survival curves for progression-free survival (PFS) and overall
survival (OS). Modified FOLFIRI.3 (a regimen combining 5-fluorouracil,
folinic acid, and irinotecan) is depicted as solid lines and modified FOLFOX
(a regimen combining folinic acid, 5-FU, and oxaliplatin) as dotted lines.
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outcomes to represent the characteristics of the two regimens,
the lack of assessment of clinical benefit or quality of life is a
limitation of our study.
In conclusion, our trial not only showed that both mFOLFIRI.3
and mFOLFOX regimens could be safely used but also showed
modest anti-cancer activities in gemcitabine-pretreated patients.
Although further clinical trials are necessary for comparison with
other regimens, these protocols may be reasonable therapeutic
options in a second-line setting for patients with advanced
pancreatic cancer, who were previously treated with gemcitabine-
based chemotherapy.
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